Apogee Therapeutics Inc.

36.87
-0.18 (-0.49%)
At close: Apr 25, 2025, 3:59 PM
36.30
-1.55%
After-hours: Apr 25, 2025, 05:30 PM EDT
-0.49%
Bid 28.6
Market Cap 2.19B
Revenue (ttm) n/a
Net Income (ttm) -182.15M
EPS (ttm) -3.3
PE Ratio (ttm) -11.17
Forward PE -6.11
Analyst Buy
Ask 40
Volume 254,118
Avg. Volume (20D) 690,117
Open 36.36
Previous Close 37.05
Day's Range 35.85 - 37.17
52-Week Range 26.20 - 63.50
Beta 1.73

About APGE

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs inclu...

Industry Biotechnology
Sector Healthcare
IPO Date Jul 14, 2023
Employees 196
Stock Exchange NASDAQ
Ticker Symbol APGE
Full Company Profile

Analyst Forecast

According to 5 analyst ratings, the average rating for APGE stock is "Buy." The 12-month stock price forecast is $89.5, which is an increase of 142.74% from the latest price.

Stock Forecasts
5 months ago
-5.14%
Apogee Therapeutics shares are trading lower. The ... Unlock content with Pro Subscription
8 months ago
+10.59%
Apogree Therapeutics shares are trading higher after the company announced its initiated dosing of its clinical trail for APG990.